Related by context. All words. (Click for frequent words.) 63 Phase IIIb 63 Randomized Study 63 Clinical Trial Results 62 multicentre randomized 61 Randomised 61 Phase III Clinical Trial 60 Phase Ib clinical 60 Controlled Trial 60 Phase III Trial 60 II Clinical Trial 60 Stent Thrombosis 60 Prospective Randomized 60 Pivotal Trial 60 phase IIa 60 ASTEROID 59 Combination REOLYSIN R 59 Phase Ib II 59 phase IIIb 59 Randomized Phase 59 JAK Inhibitor 59 Phase IIIb clinical 59 TRANSFORMS 59 SPEAR Study 59 Safinamide 59 Study Evaluating 59 multicenter prospective 59 Multicenter 59 Phase 2b Study 59 Phase 2a Clinical Trial 58 Meets Primary Endpoint 58 dose escalation clinical 58 Pulmonary Arterial Hypertension 58 phase IIb clinical 58 BOLDER II 58 Phase IIB 58 Randomized Clinical Trial 58 multicenter randomized placebo controlled 58 Pivotal Study 58 BRIM2 58 Picoplatin Efficacy After 58 TMC# C# 58 Phase 1a clinical 58 Clinical Trial Data 58 Phase 2b Clinical Trial 58 Double Blind Placebo 58 Prostate AdenoCarcinoma Treatment 58 multicenter phase 58 Phase IIb Trial 58 NO# [002] 57 MEND CABG 57 Phase #/#a 57 Placebo Controlled Trial 57 RE LY 57 Glufosfamide 57 Acute Myocardial Infarction 57 APEX PD 57 Pooled Analysis 57 ExTRACT TIMI 57 IMPACT IMmunotherapy 57 Oral Fingolimod 57 Multicenter Randomized 57 multicenter Phase II 57 Phase IIIb study 57 Deforolimus 57 Randomized Double Blind Placebo 57 Phase 1b clinical 57 subanalysis 57 Relapsed Multiple Myeloma 57 Patient Enrollment 57 Phase 2b Trial 57 Glatiramer Acetate 57 Multicenter Trial 57 ECASS 57 phase Ib 57 Initiated Phase 57 dose escalation Phase 57 multicenter multinational 57 RE LY trial 57 Randomized Phase II 57 Tesetaxel 57 pharmacokinetic PK study 57 Phase III Pivotal 56 Stent Restenosis 56 ENDEAVOR III 56 Relapsing Remitting Multiple Sclerosis 56 ENDEAVOR IV 56 randomized controlled multicenter 56 multicenter randomized 56 Nymox NX 56 Acute Ischemic Stroke 56 Prospective Randomized Trial 56 Degarelix 56 Drug Eluting Stents 56 ALLEGRO 56 Tezampanel 56 Preclinical Study 56 Catheter Ablation 56 STRIDE PD 56 multicenter randomized controlled 56 randomized controlled Phase 56 prospective multicenter 56 Multicenter Study 56 HORIZONS AMI 56 Infarct 56 Eluting Stent 56 RAVEL 56 Cloretazine ® 56 Frontman Discusses 56 Platelet Inhibition 56 multicenter placebo controlled 56 Phase 2a Trial 56 Anti Tumor Activity 56 TAXUS ATLAS 56 Placebo Controlled 56 multicentre 56 Metastatic Melanoma 56 Phase 2a clinical 56 randomized Phase III 56 First Patient Enrolled 56 FREEDOMS 56 multicenter clinical 55 Adjuvant Treatment 55 Pivotal Phase III 55 Long Lesion 55 PFO migraine 55 Microplasmin 55 randomized multicenter 55 CLL8 55 Phase IIb Clinical Trial 55 Chronic Myeloid Leukemia 55 Hepatocellular Carcinoma 55 Statistically Significant 55 Unfractionated Heparin 55 Monotherapy 55 Preclinical Data 55 Rosuvastatin 55 Multicenter Phase 55 Heart Failure Patients 55 Intervention Effectiveness 55 Ranolazine 55 NDA Submission 55 SABCS 55 Pharmacokinetic Study 55 fosbretabulin 55 Adjuvant Chemotherapy 55 multicentre randomized controlled 55 Randomized controlled 55 Phase 2b study 55 Dose Escalation 55 Hormone Refractory Prostate Cancer 55 ongoing Phase 1b 55 Controlled Study 55 Sipuleucel T 55 Long Term Efficacy 55 Confirmatory Phase 55 trial evaluating PRX# 55 HuMax EGFr 55 BOLDER 55 phase IIb trial 55 IND Filing 55 pivotal bioequivalence 55 Clinical Outcome 54 Intervention Effectiveness CATIE 54 Dose Ranging Study 54 prospective randomized multicenter 54 placebo controlled clinical 54 Phase IIb III 54 Acute Decompensated Heart Failure 54 Pivotal Clinical Trial 54 BRIM3 54 AVOREN 54 EURIDIS 54 Survival Benefit 54 Neuroprotective Effects 54 Randomized Evaluation 54 HCV SPRINT 54 ROCKET AF 54 Aggressive Reduction 54 Renal Cell Carcinoma 54 Epratuzumab 54 Venous Thromboembolism 54 Aneurysm Repair 54 Pirfenidone 54 ONTARGET 54 registrational Phase 54 Multicenter Randomized Double 54 RE MODEL 54 SPIRIT FIRST 54 Glucosamine Chondroitin Arthritis 54 PERISCOPE 54 SANTE 54 Severe Sepsis 54 Double Blind Randomized 54 riociguat 54 multicenter randomized clinical 54 Mycophenolate Mofetil 54 Initiate Phase 54 Completes Patient Enrollment 54 Sapacitabine 54 Diabetic Macular Edema DME 54 Clinical Efficacy 54 Coronary Revascularization 54 Pharmacokinetic PK 54 Combination Treatment 54 Late Breaker 54 subgroup analyzes 54 randomized multicenter trial 54 Antitumor activity 54 Randomized Double Blind 54 randomized Phase IIb 54 First Patient Dosed 54 Randomized Double blind 54 Carotid Stenting 54 Pivotal Phase 54 blinded randomized placebo controlled 54 Metastatic Colorectal Cancer 54 Stenting Trial CREST 54 Intracranial Aneurysms 54 CIMZIA TM certolizumab pegol 54 Chronic Lymphocytic Leukemia 54 ELACYT 54 CLARITY TIMI 54 Pemetrexed 54 Central Retinal Vein 54 confirmatory Phase 54 Hypertensive Patients 54 prospective multicentre 54 TACI Ig 54 LUX Lung 53 phase IIb study 53 SUCCEED trial 53 Trial Evaluating 53 Tanespimycin 53 Inflammatory Markers 53 Blind Placebo Controlled Trial 53 Brentuximab Vedotin SGN 53 CAMMS# 53 Vicriviroc 53 Diabetic Macular Edema 53 Sorafenib HCC Assessment 53 Relapsing Multiple Sclerosis 53 Myelodysplastic Syndrome MDS 53 PRECISE 53 Aflibercept 53 Stent Implantation 53 Prognostic Significance 53 multicenter randomized Phase 53 Randomized phase 53 Drug Eluting 53 NEVO 53 Phase Ib Clinical Trial 53 metastatic castration resistant 53 CUSTOM III 53 Renal Cancer 53 EXPLORE Xa 53 EINSTEIN DVT 53 placebo controlled Phase 53 CHARISMA 53 SPIRIT IV 53 PROactive Study 53 Demonstrates Efficacy 53 placebo controlled Phase III 53 Subgroup analysis 53 virus HCV protease inhibitor 53 HER2 Positive Breast Cancer 53 Hematological 53 VICTOR E3 53 RIO Lipids 53 Subgroup Analysis 53 RE LY ® 53 landmark ATHENA 53 Edge STudy 53 Refractory Angina 53 DIRECT Trial 53 interferon gamma 1b 53 ENESTnd 53 Betaferon R 53 acute PAO 53 Phase III AFFIRM 53 Male Infertility 53 Left Ventricular 53 FOLOTYN ® 53 CLARITY study 53 Phase III ALLEGRO 53 ABCSG 53 NSABP B 53 By JENNIFER LEARN 53 phase Ib clinical 53 PERSEUS 53 Blood Pressure Lowering 53 Phase III Psoriasis 53 Enzastaurin 53 Nicotine Vaccine 53 AVERROES 53 Non Alcoholic Steatohepatitis 53 Dapagliflozin 53 IIa trial 53 Patients Treated With 53 Novel Oral 53 Shows Efficacy 53 Antiviral Activity 52 TOCCATA 52 CROI 52 ACCLAIM 52 Hsp# Inhibitor 52 Personalized Immunotherapy 52 PEG IFN 52 Ocrelizumab 52 Immunotherapeutic 52 Previously Untreated 52 Cardiac Resynchronization Therapy 52 Phase 1b clinical trials 52 Phase Ib IIa 52 Ridaforolimus 52 vs. Angiography 52 Roundhouse Tapes 52 Antitumor Activity 52 PREGNANT PROCHIEVE ® 52 RADIATE 52 CHAMPION PCI 52 substudy 52 double blinded placebo 52 Granted Orphan Drug 52 Nesiritide 52 prucalopride 52 Systemic Sclerosis 52 icatibant 52 candidate CRLX# 52 Pivotal Phase II 52 budesonide foam 52 Randomized Controlled 52 CELLO 52 multicenter randomized Phase III 52 Arimidex Tamoxifen Alone 52 Improves Survival 52 metastatic malignant 52 Connective Tissue Oncology 52 Prolongs Survival 52 Overactive Bladder OAB 52 Curaxin CBLC# 52 Confirms Efficacy 52 CONQUER 52 cancer mCRC 52 Pharmacokinetic 52 Multiple Ascending Dose 52 Phase III PREGNANT PROCHIEVE 52 PEGINTRON TM 52 COPERNICUS 52 Advanced Neuroendocrine Tumors 52 PREVAIL 52 BCIRG 52 Advanced Renal Cell 52 REALITY Trial 52 GOUT 52 Phase 1b Clinical Trial 52 STICH trial 52 ARBITER 6 52 Paroxysmal Atrial Fibrillation 52 Pharmacodynamics 52 ASCEND HF 52 Tocilizumab 52 Paclitaxel Carboplatin 52 pan HDAC inhibitor 52 multicenter Phase 52 CARE HF 52 MIVI III 52 AIR CF2 52 dual endothelin receptor antagonist 52 Hepatotoxicity 52 VIVUS Qnexa 52 Endeavor Drug Eluting 52 Pralatrexate 52 Tipranavir 52 Rheumatoid Arthritis Patients 52 compound INCB# 52 relapsed MM 52 mapatumumab 51 RADIANT 51 Reveals Tracklisting 51 Patency 51 Prospective Multicenter 51 prospective randomized controlled 51 Brain Metastases 51 Chronic Heart Failure 51 registrational trial 51 Investigational Treatment 51 Phase #b/#a clinical 51 Significantly Improved 51 Pharmacokinetics PK 51 Meta Analysis 51 Gastric Cancer 51 oral dual endothelin 51 Abstract Accepted 51 DA VINCI 51 Safety Tolerability 51 IMA# 51 NICE SUGAR 51 Metastatic Renal Cell Carcinoma 51 PROTECT AF 51 SCD HeFT 51 EDEMA4 51 Phase 2b kidney transplant 51 Intervention Trial 51 Demonstrates Positive 51 Confirmatory 51 ZACTIMA 51 Carotid Revascularization Endarterectomy vs. 51 Acute Myocardial 51 CYPHER ® Sirolimus eluting 51 evaluating Actimmune 51 Bare Metal Stents 51 Radiation Induced 51 Predict Risk 51 tramiprosate Alzhemed TM 51 MEND CABG II 51 Endovascular Valve Edge 51 EDEMA3 51 Transdermal Patch 51 Activator CK # 51 CLORETAZINE TM VNP#M 51 Myocardial Ischemia 51 Commence Phase 51 CABANA 51 Antifungals 51 Bosutinib 51 TM Drug Eluting 51 Clinical Trial Evaluating 51 Anthracycline 51 Diamyd Medical Diamyd 51 Initiate Phase III 51 CURRENT OASIS 7 51 novel VDA molecule 51 Rotavirus Vaccine 51 Uterine Fibroid Embolization 51 Silodosin 51 dose escalation phase 51 Clinical Antipsychotic Trials 51 Left Ventricular Dysfunction 51 Efficacy Trial 51 Anti Tumor 51 SPRYCEL ® 51 rasagiline tablets 51 Hedgehog Pathway Inhibitor 51 TROPIC 51 MEK Inhibitor 51 mGluR5 negative 51 landmark ATHENA trial 51 Randomized Trials 51 Aurora Kinase 51 Lipid Lowering Treatment 51 Motesanib 51 Drug Shows Promise 51 Atypical Hemolytic Uremic Syndrome 51 Randomized 51 MERIT ES 51 ACCOMPLISH 51 PREVENT IV 51 Coronary Stent 51 Desvenlafaxine Succinate 51 Asthma Intervention 51 PHASE III 51 Randomized Comparison 51 Prostate Cancer Progression 51 TAXUS IV 50 zotarolimus eluting stent 50 Effectively Treats 50 Antihypertensive 50 dose escalation trial 50 Breast Cancer Cells 50 Begins Recording 50 See CLINICAL PHARMACOLOGY 50 Cardiovascular Risk Reduction 50 Myocardial Infarction Study 50 AVADO 50 controlled multicenter Phase 50 Neovascular Age Related Macular 50 Cardiac Resynchronization 50 PreCISe 50 Cardiac Allograft Rejection 50 Neoadjuvant Chemotherapy 50 familial amyloidotic polyneuropathy FAP 50 AIR CF1 50 HCV RESPOND 2 50 Phase IIA 50 Val HeFT 50 Biological Effects 50 Pharmacodynamic 50 Ziprasidone 50 SYNTAX 50 Hypoactive Sexual Desire Disorder 50 Adverse Event 50 Beneficial Effects 50 Plaque Psoriasis 50 Postmenopausal Women 50 Preclinical Models 50 IL# PE#QQR 50 Observational Study 50 Gastrointestinal Stromal Tumors 50 Novel Inhibitor 50 Chronic Hepatitis C 50 Elagolix 50 Therapy Improves 50 Initiates Phase III 50 Sirolimus Eluting Stent 50 ISTODAX ® 50 NMDA Receptor 50 Oral Calcitonin 50 Eluting Coronary Stent System 50 ACAPODENE 50 oral prodrug 50 Proc Am Soc 50 PROVENGE sipuleucel T 50 Septic Shock 50 VADT 50 Newly Diagnosed Multiple Myeloma 50 Single Dose 50 DEFER 50 Peginterferon Alfa 2a 50 acyclovir Lauriad R 50 HORIZONS AMI trial 50 Trial NLST 50 Skin Lesions 50 ATTR 50 Antitumor 50 IIa Clinical Trial 50 Cutaneous T 50 huC# DM4 50 Treatment Resistant 50 Anti VEGF 50 BARI 2D 50 ERATO 50 Pediatric Patients 50 Metastatic Prostate Cancer 50 allosteric modulator NAM 50 atypical Hemolytic Uremic Syndrome 50 FDA Accepts 50 CCX# B 50 NAVISTAR R 50 oral rivaroxaban 50 Epilepsy Drug 50 Hepatocellular Carcinoma HCC 50 Cimzia TM 50 evaluating tivozanib 50 Risk Stratification 50 Intervention Trial GAIT 50 prospective observational 50 GISSI 50 multicenter Phase III 50 Carotid Endarterectomy 50 BR.# 50 stage IIIB 50 CABERNET 49 Placebo controlled 49 Cell Lymphoma 49 Onyx Pharmaceuticals Announces 49 CYPHER Stent 49 Soft Tissue Sarcoma 49 unfractionated heparin UFH 49 Phase Ib clinical trials 49 Completes Patient Enrolment 49 Menopausal Women 49 Metabolic Efficiency 49 Dose Finding 49 Treatment Shows Promise 49 dependent kinase inhibitor 49 Annamycin 49 International Verapamil SR 49 Previously Treated 49 Shows Promising 49 Venous Thrombosis 49 Hepatitis C Infection 49 Effective Treatments 49 RNAi Therapeutics 49 Castration Resistant Prostate Cancer 49 Hodgkin lymphoma HL 49 STENT 49 including eniluracil ADH 49 NPC 1C 49 Nebulized 49 CALGB # [002] 49 Anti Clotting Drug 49 Efficacy Results 49 corticosteroid dexamethasone 49 Multiethnic Study 49 Completes Enrollment 49 Syncria R 49 FRONTMAN 49 ST Segment Elevation 49 Therapy Shows Promise 49 Afatinib 49 Long Term Outcomes 49 systemic anaplastic large 49 ENDEAVOR II 49 Quinamed 49 BLOSSOM 49 Mammalian Cell Culture 49 CYT# potent vascular disrupting 49 Demonstrates Sustained 49 Lymphocytic 49 Bare Metal Stent 49 Unmet Medical 49 THAT ARE DIFFICULT TO 49 Schizophrenia Treatment 49 Cholesterol Levels SPARCL 49 Initiates Phase II 49 Metabolic Endocrinology 49 Brain Scans 49 Prognostic Factors 49 Spinal Fluid 49 Cannabinor 49 Track Listing Revealed 49 ACTEMRA TM 49 unique alkylating agent 49 Therapeutic Efficacy 49 dasatinib Sprycel ® 49 Statistically Significant Improvement 49 Advanced Melanoma 49 relapsing remitting MS RRMS 49 Relapsed Refractory 49 phase III isavuconazole 49 Coronary Artery Bypass Graft 49 Squamous Cell Carcinoma 49 Benign Prostatic Hyperplasia 49 Randomized Controlled Trial 49 ADONIS 49 initiated Phase Ib 49 Data Suggest 49 Nonalcoholic Fatty Liver Disease 49 Teva Provides Update 49 Clinical Outcomes Utilizing Revascularization 49 investigational humanized monoclonal antibody 49 Dose Ranging 49 Dose escalation 49 complement inhibitor eculizumab 49 RIBBON 49 Therapeutic Targets 49 oral ridaforolimus 49 Genetic Markers 49 Drug Induced 49 Phase IIa Clinical Trial 49 Successfully Completes Phase 49 Dupuytren Disease 49 Presents Positive 49 RECORD1 49 recurrent metastatic ovarian cancer 49 prospective nonrandomized 49 Non Alcoholic Fatty 49 Eszopiclone 49 Evaluation WISE 49 Slows Progression 49 octreotide implant 49 Therapeutic Effects 49 MVA MUC1 IL2 49 Romidepsin 49 STEP BD 49 Multivessel Evaluation 49 Submits NDA 49 Diabet Med 49 Archexin 49 Gene Variation 49 APPRAISE 49 Heterozygous Familial Hypercholesterolemia 48 Genetic Variation 48 Idiopathic Pulmonary Fibrosis 48 Cardiac Biomarkers 48 acute peripheral arterial 48 Prostate Lung Colorectal 48 Phytotherapy Research 48 Outpatient Setting 48 TRIAL OF 48 CRMD# 48 Recurrent Breast Cancer 48 Postmarketing 48 oral transmucosal fentanyl citrate 48 Ophena TM 48 PEGylated Fab fragment 48 PANVAC VF 48 evaluating satraplatin plus 48 CML CP 48 randomized multicenter Phase III 48 Acetonide 48 Cervical Dysplasia 48 Clolar ® 48 acute mania 48 catheter occlusion 48 Synta Announces 48 + Perifosine Evaluation 48 SPARCL 48 HALTS 48 Nonalcoholic Steatohepatitis 48 Tyrosine Kinase Inhibitor 48 Darinaparsin 48 Orally Active 48 UNLOAD 48 liposome injection 48 dextromethorphan quinidine 48 indolent follicular non 48 Lupus Drug 48 Adenoma 48 Completes Dosing 48 prospective multicenter randomized 48 Therapy Reduces 48 Antiepileptic Drugs 48 Oncolytic Reovirus 48 PROactive study 48 refractory cutaneous T 48 Maximum Tolerated Dose MTD 48 Sirolimus eluting Coronary Stent 48 Patients Suffering 48 Electroencephalography 48 Atorvastatin Evaluation 48 steroid refractory ulcerative 48 Intravascular 48 Initiates Enrollment 48 Slow Progression 48 multicenter randomized double 48 Arch Neurol 48 Embolization 48 recurrent malignant glioma 48 Phase III ADT 48 Advaxis Phase 48 Schiavo Autopsy 48 multicentre randomized double 48 Hematological Cancers 48 Exherin TM 48 Non Invasive Treatment 48 ThermoDox R 48 LHRH receptor positive 48 Unstable Angina 48 candesartan cilexetil 48 Hormone Receptor Positive 48 Omacetaxine 48 rALLy 48 biliary tract cancer 48 Thrombolysis 48 alvespimycin 48 Stenting 48 KRN# 48 plus Copegus R 48 ZOLINZA 48 CATIE AD 48 Cancer Prevention ATBC 48 Silicone Breast Implant 48 cell lymphoma CTCL 48 Antigen Specific 48 Complicated Skin 48 Shows Promise Against 48 evaluating satraplatin 48 MAGE A3 ASCI 48 Improves Outcomes 48 Unresectable 48 Lancet Oncology journal 48 Osteoporosis Drugs 48 placebo controlled trials 48 ThermoDox ® clinical 48 CR# vcMMAE 48 INSPIRE Trial Phase III 48 Cancer Res 48 ERBITUX cetuximab 48 Efficacy Study 48 Early Relapsing Multiple 48 Lung Cancer Survival 48 Recurrent Glioblastoma 48 IMPACT DCM clinical 48 COSIRA trial 48 Commences Phase 48 Daclizumab 48 evaluating Prochymal 48 DEFINITIVE 48 antibody MAb 48 PSMA ADC 48 refractory chronic lymphocytic 48 samarium Sm 48 HGS ETR1 48 lexidronam injection 48 R bendamustine hydrochloride 48 IIIb 48 NEVO RES 48 Prostate Cancer Prevention 48 Leukemias 48 HGS ETR2 48 PROMUS R 48 Int J Obes Relat 48 Initiates Phase 2b 48 HDAC Inhibitor 48 Occlusive Disease 48 Carotid 48 Subarachnoid Hemorrhage 48 Finishes Recording 48 LENALIDOMIDE 48 TO AVOID PREGNANCY WHILE 48 Acta Scandinavica 48 PROSTVAC ® 48 treat benign prostatic 48 Lipid Levels 48 Elevated Levels 47 PF # [002] 47 Revascularization 47 Zenvia ™ 47 Cardiomyocytes 47 evaluating carfilzomib 47 XIENCE V PROMUS Stent 47 FDA APPROVES 47 CONQUER OB 47 Ovarian PLCO Cancer 47 Angiographic 47 WHEL 47 Pegylated Liposomal Doxorubicin 47 CAPACITY trials 47 pralatrexate injection folate analogue 47 Inflammatory Bowel Diseases 47 Gene Linked 47 AKT inhibitor 47 Patients Receiving 47 Often Misdiagnosed 47 Refractory Hodgkin Lymphoma 47 VIVITROL ® 47 No Observed Adverse 47 Treatment Experienced 47 Meta analyzes 47 Appears Safe 47 multicentre prospective 47 Brain Wiring 47 recurrent glioblastoma multiforme 47 induced macular edema 47 relapsed MCL 47 Philadelphia Chromosome Positive 47 Randomized Controlled Trials 47 Histologic 47 Prostate Cancer Recurrence 47 Raloxifene Evaluation MORE 47 Aeolus Pharmaceuticals Announces 47 Spatio Temporal 47 Active Ulcerative Colitis 47 Xcytrin R 47 FEMALES SHOULD BE ADVISED 47 PROTEGE 47 LymphoStat B belimumab 47 Presents Preclinical Data 47 relapsed refractory multiple myeloma 47 receptor tyrosine kinase inhibitor 47 REALISM 47 Randomized trials 47 Bayer HealthCare Onyx Pharmaceuticals 47 AACR San Antonio 47 Hemodialysis Patients 47 Matrix Phase 2b 47 reflux esophagitis 47 Analytical Tool 47 Topics Covered Executive 47 Enrolling Patients 47 BMC Musculoskeletal Disorders 47 CINQUIL 47 Heart Failure Therapies 47 Antiplatelet 47 Phase III HEAT 47 MIST II 47 Urgent Intervention Triage 47 Coronary Artery Calcium 47 controlled multicenter 47 ALN VSP Phase 47 fistulizing Crohn disease 47 Nicotine Addiction 47 Pegloticase 47 Survival Rates 47 LymphoStat B TM 47 monoclonal antibody conjugated 47 #th Interscience Conference 47 placebo controlled studies 47 JAK2 Inhibitor 47 #F FDG PET 47 orally administered inhibitor 47 Parathyroid Hormone 47 J Am Coll 47 Statin Drugs 47 HYVET 47 Intravitreal 47 Drug Prevents 47 Immunomedics Announces 47 number NCT# ClinicalTrials.gov 47 Combo Therapy 47 Seliciclib CYC# 47 Stem Cell Treatment 47 TRANSDUR ™ 47 ICON7 47 IMC #B 47 MKC# MT 47 Drug Coated Stents 47 Randomized Clinical Trials 47 entitled Treatment Algorithms 47 SUPPRELIN R LA 47 Antipsychotic Drug 47 Techni lab 47 IN PATIENTS WITH 47 serum phosphorous 47 Dose Escalation Study 47 AVN# Phase 47 PEGylated interferon beta 1a 47 ACCORD Lipid 47 Screening Trial 47 huN# DM1 47 Drug Combo 47 IMPACT DCM 47 placebo controlled multicenter 47 metastatic HRPC 47 Attack Trial ALLHAT 47 Psychiatric Disorders 47 generation purine nucleoside 47 Humanized Anti 46 COR Diabetes 46 Drug Eluting Stent System 46 NATRECOR ® 46 Panzem R NCD 46 Rare Genetic 46 Vascular Disrupting Agent 46 Neurol 46 CD3 monoclonal antibody 46 IIIa inhibitor 46 Receives Approvable Letter 46 Sequenced Treatment Alternatives 46 BioElectronics Announces 46 Cognitive Impairment 46 Diagnostic Criteria 46 Long Term Survival 46 liposomal formulation 46 colitis UC 46 5 fluorouracil leucovorin 46 Lowers Risk 46 SORIN 46 Electrophysiological 46 FOLFOX6 chemotherapy regimen 46 Platinol ® 46 Treatment Algorithm 46 Predictive Value 46 Insulin Therapy 46 Gene Variants 46 Sleep Disturbance 46 EMILIA 46 Vaccine Trial 46 AVANT GARDE 46 Clin Oncol 46 J Allergy Clin 46 Six Realms 46 fidaxomicin Phase 46 label multicenter Phase 46 Receives Orphan Drug Designation 46 Achieves Primary Endpoint 46 PDX pralatrexate 46 Investigational Oral 46 Cerebril TM 46 Aromatase Inhibitors 46 ICAAC IDSA 46 CLINICAL TRIAL 46 Tumor Response 46 ALLEVIATE 46 Pre RELAX AHF 46 XIENCE TM 46 oral methylnaltrexone 46 SEAMLESS 46 renal artery stenting 46 GRNCM1 46 MATCHED 46 Advanced Solid Tumors 46 Abciximab 46 vapreotide acetate 46 cancer neuroendocrine tumor 46 J Clin 46 Colorectal Cancers 46 Prolongs Life 46 plasma kallikrein inhibitor 46 Node Positive 46 occlusion CRVO 46 Prognostic Value 46 paclitaxel poliglumex 46 Breast Carcinoma 46 ABLYNX 46 Doxil ® 46 cetuximab Erbitux R 46 selective modulator 46 Stenting Trial 46 Gene Silencing 46 pharmacodynamic profiles 46 Contrast Enhanced 46 PRELUDE 46 oral nucleoside analogue 46 genotypic resistance 46 multicenter trials 46 Mg Usa 46 Diffuse Large B 46 rALLy clinical trial 46 metastatic castrate resistant 46 Primary Endpoint 46 Anti Bacterial Envelope 46 MKC# MKC# PP 46 PCI ExTRACT TIMI 46 iPrEx 46 TM Everolimus Eluting 46 Potentially Fatal 46 label multicenter